{"id":"tebipenem-pivoxil","rwe":[],"tags":[{"label":"tebipenem pivoxil","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"J01DH06","category":"atc"},{"label":"Active","category":"status"}],"phase":"phase_3","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"orapenem","offLabel":[],"synonyms":["tebipenem pivoxil","orapenem"],"timeline":[],"aiSummary":"Orapenem is a small molecule that inhibits bacterial penicillin-binding protein. It is being studied as an alternative to Ceftriaxone for treating clinically non-responding children with Shigellosis.","approvals":[],"brandName":"Orapenem","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"tebipenem pivoxil","explanation":"Think of the bacterial cell wall like a brick wall. Orapenem blocks the enzyme that helps put the bricks together, causing the wall to weaken and eventually collapse. This ultimately leads to the death of the bacterial cell.","oneSentence":"Orapenem works by inhibiting the bacterial enzyme transpeptidase, which is essential for bacterial cell wall synthesis.","technicalDetail":"Orapenem specifically inhibits the activity of the transpeptidase enzyme, which is responsible for the cross-linking of peptidoglycan chains in the bacterial cell wall, ultimately leading to cell lysis and death."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2574","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=TEBIPENEM%20PIVOXIL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TEBIPENEM PIVOXIL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:48:47.455994","biosimilars":[],"competitors":[{"drugName":"meropenem","drugSlug":"meropenem","fdaApproval":"1996-06-21","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ertapenem","drugSlug":"ertapenem","fdaApproval":"2001-11-21","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"doripenem","drugSlug":"doripenem","fdaApproval":"2007-10-12","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"cilastatin","drugSlug":"cilastatin","fdaApproval":"1985-11-26","relationship":"same-class"},{"drugName":"imipenem","drugSlug":"imipenem","fdaApproval":"1985-11-26","relationship":"same-class"},{"drugName":"vaborbactam","drugSlug":"vaborbactam","fdaApproval":"2017-08-29","relationship":"same-class"},{"drugName":"relebactam","drugSlug":"relebactam","fdaApproval":"2019-06-16","relationship":"same-class"}],"genericName":"tebipenem pivoxil","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"meropenem","brandName":"meropenem","genericName":"meropenem","approvalYear":"1996","relationship":"same-class"},{"drugId":"ertapenem","brandName":"ertapenem","genericName":"ertapenem","approvalYear":"2001","relationship":"same-class"},{"drugId":"doripenem","brandName":"doripenem","genericName":"doripenem","approvalYear":"2007","relationship":"same-class"},{"drugId":"cilastatin","brandName":"cilastatin","genericName":"cilastatin","approvalYear":"1985","relationship":"same-class"},{"drugId":"imipenem","brandName":"imipenem","genericName":"imipenem","approvalYear":"1985","relationship":"same-class"},{"drugId":"vaborbactam","brandName":"vaborbactam","genericName":"vaborbactam","approvalYear":"2017","relationship":"same-class"},{"drugId":"relebactam","brandName":"relebactam","genericName":"relebactam","approvalYear":"2019","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06059846","phase":"PHASE3","title":"A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)","status":"COMPLETED","sponsor":"Spero Therapeutics","startDate":"2023-12-21","conditions":["Urinary Tract Infection","Acute Pyelonephritis"],"enrollment":1690,"completionDate":"2025-02-06"},{"nctId":"NCT07236944","phase":"PHASE4","title":"Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care","status":"RECRUITING","sponsor":"Uppsala University","startDate":"2025-12","conditions":["Febrile Urinary Tract Infection"],"enrollment":560,"completionDate":"2029-03"},{"nctId":"NCT05121974","phase":"PHASE2","title":"Tebipenem Trial in Children With Shigellosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2022-08-18","conditions":["Shigellosis"],"enrollment":132,"completionDate":"2026-08-17"},{"nctId":"NCT06727136","phase":"PHASE1","title":"A Study to Characterize Single and Repeat Dose Pharmacokinetics of Tebipenem-Pivoxil-Hydrobromide (TBP-PI-HBr) and Its Major Metabolite (SPR1349) in Healthy Participants","status":"COMPLETED","sponsor":"Spero Therapeutics","startDate":"2024-11-20","conditions":["Healthy Participants"],"enrollment":39,"completionDate":"2025-04-22"},{"nctId":"NCT05856747","phase":"PHASE1","title":"A Study to Compare Two Bioanalytical Assays for Tebipenem","status":"COMPLETED","sponsor":"Spero Therapeutics","startDate":"2023-05-04","conditions":["Healthy Volunteers"],"enrollment":20,"completionDate":"2023-06-01"},{"nctId":"NCT04919954","phase":"PHASE1","title":"Tebipenem (SPR994) Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis","status":"COMPLETED","sponsor":"Hartford Hospital","startDate":"2021-07-01","conditions":["Diabetes","Wound Infection","ABSSSI","Healthy Volunteers"],"enrollment":12,"completionDate":"2022-12-23"},{"nctId":"NCT03788967","phase":"PHASE3","title":"Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)","status":"COMPLETED","sponsor":"Spero Therapeutics","startDate":"2019-06-03","conditions":["Complicated Urinary Tract Infection","Acute Pyelonephritis"],"enrollment":1372,"completionDate":"2020-05-27"},{"nctId":"NCT04376554","phase":"PHASE1","title":"Effect of Tebipenem on Normal Human Intestinal Microbiota","status":"COMPLETED","sponsor":"Spero Therapeutics","startDate":"2020-02-10","conditions":["Healthy Volunteers"],"enrollment":30,"completionDate":"2021-04-06"},{"nctId":"NCT04178577","phase":"PHASE1","title":"Phase 1 Study of PK and Safety of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Subjects With Various Degrees Of Renal Function","status":"COMPLETED","sponsor":"Spero Therapeutics","startDate":"2019-12-06","conditions":["Renal Impairment"],"enrollment":39,"completionDate":"2020-09-11"},{"nctId":"NCT04625855","phase":"PHASE1","title":"Study of the Absorption, Metabolism, and Excretion of [14C]-Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) Following a Single Oral Dose in Healthy Male Subjects","status":"COMPLETED","sponsor":"Spero Therapeutics","startDate":"2020-09-30","conditions":["Healthy Volunteers"],"enrollment":8,"completionDate":"2020-10-16"},{"nctId":"NCT04368585","phase":"PHASE1","title":"Study to Examine the Effect of Antacid and Omeprazole on the Single-Dose Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Spero Therapeutics","startDate":"2020-07-01","conditions":["Healthy Volunteers"],"enrollment":20,"completionDate":"2020-08-21"},{"nctId":"NCT04421885","phase":"PHASE1","title":"Bioequivalence Study Comparing Two Tablet Formulations of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Spero Therapeutics","startDate":"2020-06-01","conditions":["Healthy Volunteers"],"enrollment":36,"completionDate":"2020-07-29"},{"nctId":"NCT04238195","phase":"PHASE1","title":"A Single-Dose, Randomized, Placebo- and Active-Control, Four-Way, Cross-Over Study for the Evaluation of the Effect of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) on the QT/QTc Intervals in Adult Healthy Subjects","status":"COMPLETED","sponsor":"Spero Therapeutics","startDate":"2020-01-19","conditions":["TQT Study"],"enrollment":24,"completionDate":"2020-02-26"},{"nctId":"NCT03395249","phase":"PHASE1","title":"Phase 1 Study of Safety, Tolerability and Pharmacokinetics of SPR994","status":"COMPLETED","sponsor":"Spero Therapeutics","startDate":"2017-10-20","conditions":["Healthy Volunteers"],"enrollment":124,"completionDate":"2018-08-02"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"95AK1A52I8","CHEBI":"CHEBI:135799","INN_ID":"7924","UMLSCUI":"C2699902","ChEMBL_ID":"CHEMBL2107486","KEGG_DRUG":"D09598","DRUGBANK_ID":"DB16840","PDB_CHEM_ID":" 1TE","PUBCHEM_CID":"9892071","IUPHAR_LIGAND_ID":"10864","SECONDARY_CAS_RN":"161715-21-5","MESH_SUPPLEMENTAL_RECORD_UI":"C120999"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":67,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"J01DH06","allCodes":["J01DH06"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}